Lyra Therapeutics to Present at Jefferies Healthcare Conference
02 Junio 2023 - 6:30AM
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage
biotechnology company developing innovative therapies for the
localized treatment of patients with chronic rhinosinusitis (CRS),
today announced that Maria Palasis, Ph.D., President and Chief
Executive Officer, will present at the Jefferies Healthcare
Conference in New York, NY on Wednesday, June 7, 2023, at 10:30
a.m. ET.
A live webcast of the presentation will be
available on the Investor Relations section of the Company's
website at investors.lyratherapeutics.com. A replay of the webcast
will be available for 30 days following the presentation.
About Lyra
Therapeutics
Lyra Therapeutics, Inc. is a clinical-stage
biotechnology company developing therapies for the localized
treatment of patients with chronic rhinosinusitis (CRS). Lyra has
two investigational product candidates, LYR-210 and LYR-220, in
late-stage development for CRS, a highly prevalent inflammatory
disease of the paranasal sinuses which leads to debilitating
symptoms and significant morbidities. LYR-210 and LYR-220 are
bioresorbable nasal implants designed to be administered in a
brief, in-office procedure and are intended to deliver six months
of continuous mometasone furoate drug therapy (7500µg MF) to the
sinonasal passages. LYR-210 is designed for surgically naïve
patients and is being evaluated in the ENLIGHTEN Phase 3 clinical
program, while LYR-220, an enlarged implant, is being evaluated in
the BEACON Phase 2 clinical trial in patients who have recurrent
symptoms despite having had prior ethmoid sinus surgery. These two
product candidates are designed to treat the estimated four million
CRS patients in the United States who fail medical management each
year.
Contact Information:Ellen
Cavaleri, Investor Relations 615.618.6228 ecavaleri@lyratx.com
Lyra Therapeutics (NASDAQ:LYRA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Lyra Therapeutics (NASDAQ:LYRA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024